Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization.

ABSTRACT: Several effective SARS-CoV-2 vaccines are currently in use, but effective boosters are needed to maintain or increase immunity due to waning responses and the emergence of novel variants. Here we report that intranasal vaccinations with adenovirus 5 and 19a vectored vaccines following a systemic plasmid DNA or mRNA priming result in systemic and mucosal immunity in mice. In contrast to two intramuscular applications of an mRNA vaccine, intranasal boosts with adenoviral vectors induce high levels of mucosal IgA and lung-resident memory T cells (T_RM); mucosal neutralization of virus variants of concern is also enhanced. The mRNA prime provokes a comprehensive T cell response consisting of circulating and lung T_RM after the boost, while the plasmid DNA prime induces most

SUBMITTER: Lapuente D 

PROVIDER: S-EPMC8626513 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature